Y mAbs Therapeutics

Y mAbs Therapeutics — Q1 2024 Earnings Presentation

20 slides from Y mAbs Therapeutics's earnings presentation, May 8, 2024

  1. Slide 1: Q1 2024 Financial Results and Corporate Update

    Q1 2024 Financial Results and Corporate Update May 8, 2024

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this pre

  3. Slide 3: Company Overview

    Mike Rossi President and CEO Company Overview 3

  4. Slide 4: Agenda

    Agenda Company Overview 1 Mike Rossi, President and Chief Executive Officer DANYELZA Global Sales 2 Sue Smith, Chief Commercial Officer Naxitamab Development Program 3 Vignesh Rajah, MBBS, DCH, MRCP, Chief Medical Officer Q1 2024 Financials 4 Bo Kruse, Chief Financial Officer Q&A 5 All and Thomas Ga

  5. Slide 5: DANYELZA Highlights

    DANYELZA Highlights • Q1 2024 U.S. DANYELZA net product revenues of $18.6 million,  11% YoY • 63 sites activated to date since DANYELZA commercial launch • 5 new accounts added in Q1 2024 • Continued global expansion with China commercial progress • Partner Adium launched in Brazil and Mexico in Q2

  6. Slide 6: Study 1001: GD2-SADA Phase I Clinical Trial – Dosing Patients in Part A

    Study 1001: GD2-SADA Phase I Clinical Trial – Dosing Patients in Part A Theranostic approach using a 30 mCi 177Lu-DOTA imaging dose before exposing to therapeutic dose Trial Update: › Solid tumors (SCLC, malignant melanoma, sarcomas) › 14 patients dosed* › Completed Cohorts 1, 2 and 3; currently in

  7. Slide 7: Study 1201: Planned CD38-SADA Phase I Clinical Trial Design

    Study 1201: Planned CD38-SADA Phase I Clinical Trial Design Theranostic approach using CD38 positivity on IHC and 177Lu-DOTA organ dosimetry before repeat dosing in patients with relapsed or refractory non-Hodgkin Lymphoma Trial Update: › IND approved by U.S. FDA in Q4 2023 › Anticipate activating f

  8. Slide 8: Global DANYELZA Sales

    Mike Rossi President and CEO Company Overview 8

  9. Slide 9: Global DANYELZA Sales

    Sue Smith Chief Commercial Officer Global DANYELZA Sales 9

  10. Slide 10: Q1 2024 DANYELZA Global Commercial Update

    Q1 2024 DANYELZA Global Commercial Update • Q1 2024 U.S. DANYELZA net product revenues of $18.6 million,  11% YoY • Majority of total sales in U.S.; additional sales recorded in China, LATAM • 63 U.S. accounts to date since initial launch; 5 new accounts added in Q1 2024 • 18 U.S. HCPs prescribed D

  11. Slide 11: Naxitamab Development Program

    Vignesh Rajah Chief Medical Officer Naxitamab Development Program 11

  12. Slide 12: Ongoing Naxitamab Clinical Trials

    Ongoing Naxitamab Clinical Trials • Phase II BCC multi- • Multi-center Phase II trial • ISS Phase Ib/II trial • Randomized Phase II trial center trial evaluating investigating naxitamab investigating TGFβ NKs, evaluating efficacy and naxitamab + standard in patients with relapsed gemcitabine + naxit

  13. Slide 13: Q1 2024 Financials

    Bo Kruse Chief Financial Officer Q1 2024 Financials 13

  14. Slide 14: Key Q1 2024 Financial Highlights: Revenue

    Key Q1 2024 Financial Highlights Revenue Three months ended Mar 31, 2024 2023 Net product revenue $19.4 M $20.3M License revenue $0.5 M – Total revenue $19.9 M $20.3 M Net product revenue  4% YoY 14

  15. Slide 15: Key Q1 2024 Financial Highlights: Operating Expenses

    Key Q1 2024 Financial Highlights Operating Expenses Three months ended Mar 31, 2024 2023 Cost of goods sold $2.1 M $2.1 M License royalties $0.05 M – Research & development $13.3 M $13.4 M Selling, general & admin $11.4 M $12.3 M Total OpEx $26.8 M $27.8 M  3% YoY 15

  16. Slide 16: Key Q1 2024 Financial Highlights: Net Loss

    Key Q1 2024 Financial Highlights Net Loss Three months ended Mar 31, 2024 2023 Net loss $(6.6) M $(6.4) M Net loss per basic, diluted share $(0.15) $(0.15) Net loss relatively flat YoY 16

  17. Slide 17: Key Q1 2024 Financial Highlights: Cash

    Key Q1 2024 Financial Highlights Responsible stewards of capital As of Three months ended Mar 31, Mar 31, 2024 Dec 31, 2023 2024 2023 Cash and cash equivalents $75.7 M $78.6 M Cash use $2.9 M $13.1 M Anticipated cash runway Quarterly cash use into 2027*  78% YoY *This estimate reflects the Company'

  18. Slide 18: Reiterate Financial Guidance for Full Year 2024

    Reiterate Financial Guidance for Full Year 2024 DANYELZA Net Product Revenues: $95 million to $100 million Total Operating Expenses: $115 million to $120 million Total Expected Cash Burn: $15 million to $20 million Cash and cash equivalents anticipated to support operations as currently planned into

  19. Slide 19: Q&A

    Q&A Mike Rossi Sue Smith Vignesh Rajah, MBBS, President and Chief Commercial Officer DCH, MRCP Chief Executive Officer Chief Medical Officer Thomas Gad Bo Kruse Founder, Vice Chair, Chief Financial Officer Chief Business Officer 19

  20. Slide 20: Thank You

    Thank You

Y-mAbs Therapeutics — Q1 2024 Earnings Presentation on 6ix